Sun Pharmaceutical Industries has announced the Unaudited Standalone results for the Quarter ended December 31, 2016. The Company has posted a net loss of Rs (1626.60) million for the quarter ended December 31, 2016 as compared to net loss of Rs (1422.70) million for the quarter ended December 31, 2015. Total Income has increased from Rs 19283.90 million for the quarter ended December 31, 2015 to Rs 20128.10 million for the quarter ended December 31, 2016. The company also announced the Unaudited Consolidated results for the Quarter ended December 31, 2016. The Group has posted a net profit after taxes, non-controlling interest and share of profit of associates & joint ventures of Rs 14718.20 million for the quarter ended December 31, 2016 as compared to Rs 15448.50 million for the quarter ended December 31, 2015. Total Income has increased from Rs 72952.00 million for the quarter ended December 31, 2015 to Rs 80348.10 million for the quarter ended December 31, 2016.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1836.70 |
| Dr. Reddys Lab | 1306.75 |
| Cipla | 1371.70 |
| Zydus Lifesciences | 939.65 |
| Lupin | 2464.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: